Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siplizumab-based Conditioning for Stem Cell Transplant in Advanced Sickle Cell Disease
NCT06078696Phase 2Terminated
- Sponsor
- Columbia University
- Start
- Sep 2023
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of siplizumab in sickle cell anemia (SCA), sponsored by Columbia University. Primary endpoint: Failure Rate at 12 months. Started Sep 2023; status: terminated.
02
Drugs
siplizumab
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on NCT06078696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06078696.